Low Risk MDS Webinar
In this webinar, Dr. Jose Martinez discuesse the diagnosis of Low Risk MDS and treatment options available to patients.
diagnosis
Correlates and consequences of clonal hematopoiesis expansion rate: a 16-year longitudinal study of 6976 women
Abstract
Finding His Way Through: Evan’s Story of PNH
Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings
Please find all content at the link.
Curing the Incurable: TP53 Mutated Myeloid Neoplasms
Abstract
What is PNH? Webinar
In this webinar, Dr. Srinivasa Sanikommu discusses the diagnosis of PNH and current treatments available to patients.
IHC Testing Could Serve as Surrogate to NGS for Early Detection of TP53-Mutant MDS/AML
A clinical guide to TP53 mutations in myeloid neoplasms
TP53 mutations are found in 10-15% of myeloid neoplasms and are one of its most important prognostic factors. Emerging data show that TP53 mutational allele status is a key determinant of clinical outcomes, with multi-hit TP53 mutant myeloid neoplasms having a very poor prognosis. Significant differences exist among the methods used in clinical and research settings to assess TP53 mutational status, leading to variability in reported patient characteristics, response to therapy, and survival.
Combo eprenetapopt plus azacitidine is well-tolerated in TP53-mutated MDS and AML
Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancy
Abstract